reports
- Stefano Toffano
- Wim Gille
Bpost : A very busy quarter (despite being relatively small)
>New reporting structure and integration of Staci - Bpost continues to experience pressures from all the volatility at the company as well as weakish end-market (mainly North America). Group operating income (i.c. revenue) for the quarter came in at € 1,025m, +4.7% yoy and -2% vs ccs and AAOBe. Adjusted EBIT came in at € 10m, in line with css. Bpost’s results were mainly driven by the new International 3PL division which now includes Staci. Pressure remains from the c...
- ING Helpdesk
Benelux Morning Notes
Aperam: 3Q24 results solid, reassuring 4Q24 guidance. bpost: 3Q24 results and FY24 outlook in line. Eurocommercial Properties: Solid results, guidance confirmed at the top of the range. Euronext: A €300m buyback is next. IMCD: In line 3Q24. SBM Offshore: Prosperity taken out. Sif Group: Line 2 now also reporting for duty
- Sharad Kumar S.P
GBL Capital Markets Day
Yesterday, GBL hosted its CMD which included some 2027E targets for the approximate allocations to different sub-portfolios – what stood out was that the weight of listed assets would reduce from 60.0%+ currently to approximately 50.0% while private assets (direct private + GBL capital) could reach a weight of 55.0% (upper-end) within GBL's portfolio. We think that a private asset weight of more than 50.0% would make GBL more attractive since its portfolio will be only one of the few ways to gai...
- Hilde Van Boxstael
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
- ING Helpdesk
Benelux Morning Notes
Aalberts: Building already bottoming, industry tough. Air France-KLM: Nobody helps. Alfen: Covenant agreement, hikes output Smart Grid. AMG: Sweet for 2024F, sour for 2025F. ArcelorMittal: 3Q24 EBITDA beats by 6%, FCF solid. BAM: 3Q beats, on its way to reach FY guidance. CMB.TECH: 3Q and FY24 reasonable but then more challenges. D'Ieteren: EGM and dividend dates announced; Belron US peer Boyd disappointing 3Q24. GBL: Double-digit TSR expected over 2024-27F. KBC: 3Q better acro...
- Thomas Couvreur
GBL 3Q24: NAV Up 3.6% To €118 & Capital Markets Day Today
As of 3Q-end, GBL's NAVps stood at €117.99, up 3.6% compared to 1H FY24 (€113.9). On a YTD basis, GBL's disposals of listed assets has helped crystallise capital gains of €1.1b (€630.0m during 9M'24 and €422.0m coming from forward sales that matured on 24th Oct'24). Notably, the stake in Adidas has been cut in half from 7.6% to 3.51%. GBL continues to have an attractive overall liquidity profile of €4.3b, which should be sufficient to seize an opportunities over the short to medium-term. We note...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
MaaT Pharma présentera une mise à jour des données issues de son progr...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce que les données mises à jour issues du programme d'accès compassionnel (Early Access Program ou EAP) en Europe portant sur 154 patients atteints de la maladie du greffon contre l’hôte gastro-intestinale (GI-aGvH) réfractaire aux stéroïdes (SR) ou dépendante aux stéroïdes ...
MaaT Pharma to Present Updates from Early Access Program at the 2024 A...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that updated results from its Early Access Program of MaaT013 in 154 patients with steroid-refractory (SR) or dependent (SD) gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) have been selected for poster presentation at the . GI-aGvHD is a major cause of morbidity and mortality following allogene...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
ASH abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at ASH (7-10 December) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (digging deeper into the obe-cel dataset), Galapagos (more CAR-T data and pre-clinical data on TCR-T) and MaaT (early access program in aGvHD):
MaaT Pharma publie ses résultats financiers pour le troisième trimestr...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd'hui un point sur ses activités et la publication de sa trésorerie et de son chiffre d’affaires jusqu'au 30 septembre 2024. Faits cliniques marquants MaaT013 Hémato-oncologie : En , MaaT Pharma a annoncé que les lots de MaaT013 étaient produits et prêts à êtr...
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provided a business update and reported its cash position and revenue as of September 30, 2024. Pipeline highlights MaaT013 In hemato-oncology: In , MaaT Pharma announced that MaaT013 batches were ready for distribution for clinical supply in the US and that MaaT Pharma advanced the readiness phase for th...
- Sharad Kumar S.P
Holdings Report - October 2024 KBCS Holdings Universe Returns -2.5% Du...
1M Performance - Absolute: During Oct'24 (1M period), the KBCS Holdings Universe posted a return of -2.5% which was mainly driven by single-asset holdings (-2.8%) while multi-asset holdings posted a slightly less negative return of -2.3%. The 3 top performers during the period were Financière de Tubize (+6.7%), D'Ieteren Group (+4.5%), and Solvac (+2.8%) while the 3 worst performers were Sofina (-11.4%), Gimv (-9.8%), and Compagnie du Bois Sauvage (-6.3%). YTD Performance - Relative: On a YTD ...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
ROCK WHITESTONE GROUP
- ING Helpdesk
Benelux Morning Notes
Aedifica: Good top line, portfolio stabilising, guidance marginally revised upward. Ageas: China Taiping Life 3Q Solvency remains strong. ASM: 3Q24 results – That's a relief - FY25 guide narrowed upwards. Belgian Telecoms: Peer Telenet 3Q24 results, still losing shares. Fugro: Focus on EBITDA and orderbook. GBL: Kicking off its trainers and cashing in €0.6bn. Colruyt: To operate 100 OKay City stores by 2032F. Heijmans: Preview - Progressing well. KPN: VodafoneZiggo 3Q24 show still weak pe...
GBLB GROUPE BRUXELLES LAMBERT SA
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
AGS AGEAS SA/NV
WKL WOLTERS KLUWER NV
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
LOTB LOTUS BAKERIES NV
HEIJM HEIJMANS N.V. CERT
AED ROYAL VOPAK NV
MELE AEDIFICA SA
ASML MELEXIS NV
OBEL ASML HOLDING NV
FUR ORANGE BELGIUM SA
FUGRO NV
- Guy Sips
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Michiel Declercq
bpost Staci, a make or break story
Running up the 3Q24 results on November 8th, we have adjusted our estimates and incorporated the Staci acquisition in our model. We now estimate the Adj. EBIT for FY24 to come in at the low end of the guided range, as we expect 3Q24 to be a softer quarter than usual driven by the impact of the press concession and though environment in the US. Looking at 2025, we expect some of these headwinds to continue. Additionally, the high transaction multiple that was paid for Staci will significantly inc...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.